Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study (vol 185, pg 13, 2020)

•The Hokusai VTE Cancer Study was a randomized controlled trial for cancer patients.•It randomized patients to either edoxaban or dalteparin for the treatment of VTE.•This analysis provides adjudicated study outcomes for all large cancer groups.•In most cancers, the primary outcome was comparable between both regimens.•The major bleeding risk in gastrointestinal cancer is higher in edoxaban recipients.